Compositions containing sodium pyruvate and application thereof

A technology of sodium pyruvate and composition, which is applied in the fields of drug combination, food science, anhydride/acid/halide active ingredients, etc., can solve the problems of no effective physiological effect, long-term tolerance, and clinical inability

Pending Publication Date: 2020-03-06
周方强
View PDF2 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] However, one-time oral administration of large doses of pyruvate (>10-15g) has obvious gastrointestinal irritation symptoms: abdominal pain, diarrhea, etc., and cannot be tolerated for a long time, so it cannot be really used in clinical practice
At the same time, the literature has confirmed that o

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Compositions containing sodium pyruvate and application thereof
  • Compositions containing sodium pyruvate and application thereof
  • Compositions containing sodium pyruvate and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0086] Reagent preparation:

[0087] Drug group: 0.35% sodium pyruvate, 0.2% sodium chloride, 0.15% potassium chloride and 1.35% glucose formula aqueous solution, instead of conventional animal laboratory drinking water;

[0088] Normal group: routine laboratory animal drinking water;

[0089] Control group: 1.0% sodium pyruvate aqueous solution, instead of drinking water in the conventional animal laboratory.

experiment Embodiment 1

[0091] Experimental animals:

[0092] Normal group: C57BLKS / J normal untreated mice: drinking regular laboratory drinking water;

[0093] Control group: C57BLKS / J diabetes db / db untreated mice (conventional human type II diabetes animal experimental model): drinking regular laboratory drinking water;

[0094] 1% Pyr: Drink db / db mice containing pure 1% sodium pyruvate distilled water to replace regular laboratory drinking water;

[0095] Drug group: Drinking an aqueous solution containing the sodium pyruvate composition of the present invention to replace conventional laboratory drinking water db / db mice, which contains 0.35% sodium pyruvate, 0.2% sodium chloride, 0.15% chlorination Potassium and 1.35% glucose.

[0096] experimental method:

[0097] The above randomly selected diabetic mice (10 weeks old) were divided into three groups, and the normal mouse group of the same strain drank different experimental water respectively, and observed and recorded under the same experimental con...

experiment Embodiment 2

[0133] Cell experiment

[0134] Human renal tubular epithelial cell line: HK-2 cells are combined with 0.5 mmol / L sodium pyruvate (5 times the normal serum level) under high glucose (30mmol / L) and normal levels (5mmol / L) conditions: previous experiments It has been confirmed that oral administration of the above sodium pyruvate composition can increase the level of pyruvate by more than 5 times in animal plasma[15]) and incubate together for 3 days. The determination method by routine experiment: Western Blot method to determine AR PDH / PDHA1 ( The main active components in PDH) and pyruvate dehydrogenase kinase (PDK) activity, the results showed the same as the above in vivo experimental results: inhibition of enhanced AR and PDK, restored PDH and PDHA1 activity.

[0135] It is worth noting that PDK in human cells will be stimulated and enhanced by many other pathogenic factors besides high glucose, such as hypoxia, oxidative stress, tumor or aging; PDK is the kinase of PDH, which ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses an oral composition containing sodium pyruvate and application thereof. The composition is prepared from the following necessary components in parts by weight: (a) 2.0 to 25.0parts by weight of sodium pyruvate; and (b) 5.0 to 100.0 parts by weight of anhydrous dextrose or other carbohydrates. The composition can be used for treating diabetes mellitus and organ complications of diabetes mellitus, or can be used for improving the activity of Pyruvate Dehydrogenase (PDH).

Description

Technical field [0001] The present invention relates to the field of drug therapy, in particular to an oral composition containing sodium pyruvate to treat diabetes and its organ complications, and non-diabetic-induced pyruvate dehydrogenase (PDH) activity reduction related diseases. Background technique [0002] Diabetes is a common disease at home and abroad. According to the statistics of the International Diabetes Federation, there were approximately 415 million patients worldwide in 2015; the domestic incidence rate among adults was approximately 10.9% in 2013 [1,2]; currently, there are more than 114 million adult diabetes patients in China. The rate is still rising. Although there are a variety of specific therapeutic drugs, there is still a lack of ideal drugs that act on multiple links in the pathogenesis; effective prevention and treatment measures are still lacking in a large area of ​​population. Diabetes is a disorder of systemic glucose oxidation and metabolism, w...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A23L33/125A23L33/10A61K31/19A61P3/10A61P3/08
CPCA23L33/125A23L33/10A61K31/19A61P3/10A61P3/08A23V2002/00
Inventor 周方强
Owner 周方强
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap